Journal of Clinical Oncology
Articles in this Issue
Prognostic value of PSA nadir ≤0.2 ng/mL in metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
5100 Background: The treatment landscape for metastatic castration-sensitive prostate cancer (mCSPC) has changed substanti...
Durable clinical benefit with B-cell maturation antigen (BCMA)–directed therapy, belantamab mafodotin plus pomalidomide and dexamethasone (BPd) in relapsed/refractory multiple myeloma (RRMM): DREAMM-8 long-term responder (LTR) analysis.
7565 Background: BCMA–directed therapies have changed the RRMM treatment landscape. In the phase 3, open-label, randomized...
Assessing risk and benefit of adjuvant therapy in stage IB NSCLC.
e20036 Background: The role of adjuvant treatment in stage IB non–small cell lung cancer (NSCLC) remains controversial. In...
Protocol for ADHERE: A randomised controlled trial evaluating a digital exercise intervention with virtual supervised group exercise sessions compared to standard of care for patients receiving androgen deprivation therapy for prostate cancer.
TPS5132 Background: In the UK, supervised exercise is recommended by NICE for prostate cancer patients receiving androgen...
Impact of primary tumor location on treatment and outcomes in Ewing sarcoma.
e23507 Background: Ewing sarcoma is an aggressive primary bone malignancy that arises in various anatomic locations. While...
Reporting of sex-related data in landmark phase III solid tumor trials presented at ASCO 2025.
11088 Background: Sex-related differences may influence cancer biology, treatment efficacy, and toxicity. Although conside...
Somatic and actionable genomic alterations in early-onset colorectal cancer versus late-onset disease: Experience from a western Florida tertiary referral center.
e15718 Background: The incidence of early-onset colorectal cancer (EOCRC) is increasing, yet its molecular and therapeutic...
Evaluation of survival after chemo-immunotherapy in veterans with extensive-stage small cell lung cancer and brain metastases.
8110 Background: Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive malignancy with rapid progression and p...
Targeting TP53 pathologic variants for cancer immunotherapy using a self-replicating mRNA vaccine strategy.
3085 Background: TP53 pathogenic variants (PVs) are highly prevalent in human malignancies as a whole...
National trends, disparities, and inpatient outcomes in appendiceal adenocarcinoma: A U.S. nationwide analysis, 2016–2021.
e23356 Background: Appendiceal adenocarcinoma is a rare gastrointestinal malignancy with heterogeneous inpatient managemen...
Understanding the awareness-to-enrollment gap: An assessment of oncologist barriers in clinical trial accrual.
e13689 Background: Adult cancer clinical trial accrual remains critically low. Physician awareness is vital to increasing...
A multicenter randomized phase II trial assessing the efficacy and safety of mCapOX plus cetuximab with mFOLFOX6 plus cetuximab as first-line treatment for <i>RAS/BRAF</i> wild-type metastatic colorectal cancer: Updated results from the CAPCET study.
3598 Background: The CAPCET study was designed to assess the efficacy and safety of modified capecitabine and oxaliplatin...
A phase II trial of trifluridine/tipiracil plus oxaliplatin in patients with advanced or metastatic biliary tract cancer following first-line therapy.
TPS4258 Background: Biliary tract cancers (BTCs) comprising of intrahepatic and extrahepatic cholangiocarcinoma and gallbl...
Impact of early tacrolimus levels on survival outcomes following allogeneic hematopoietic stem cell transplantation.
e18563 Background: Tacrolimus is routinely used for graft-versus-host disease (GVHD) prophylaxis after allogeneic hematopo...
ctDNA versus PET/CT at end of treatment in large B-cell lymphoma: A diagnostic accuracy meta-analysis.
e19090 Background: PET/CT remains crucial for end-of-treatment (EOT) evaluation in large B-cell lymphoma (LBCL), but low s...
Phase 2 study of ivonescimab in patients with cutaneous squamous cell carcinoma.
TPS9615 Background: Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer. In the setting of unre...
Remote activity monitoring to detect physical function decline and unexpected medical events in patients with prostate cancer undergoing androgen deprivation therapy.
5084 Background: Among patients with prostate cancer (PC), treatment with androgen deprivation therapy (ADT) is associated...
Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein–targeting antibody-drug conjugate: Results from patients with head and neck squamous cell carcinoma (HNSCC).
6027 Background: c-Met protein is expressed in several tumor types, including HNSCC, and is associated with a poor prognos...
Pemigatinib for untreated unresectable/metastatic cholangiocarcinoma (mCCA) with fibroblast growth factor receptor-2 (FGFR2) rearrangement: Phase 3 FIGHT-302 results.
4017 Background: First-line mCCA treatment is chemotherapy and immunotherapy. Based on the phase 2 FIGHT-202 trial, pemiga...
Second-line options in patients with BRAF-negative advanced melanoma following progression on anti-PD-1 therapy: A retrospective observational study from two centers in Russia.
e21519 Background: While anti-PD-1 is the first-line (1L) standard for BRAFwt advanced melanoma (aM), disease progression...
Impact of diabetes and glycemic control on pathologic complete response after neoadjuvant chemotherapy in breast cancer in an Afro-Caribbean population: A retrospective cohort study.
e12625 Background: Diabetes mellitus and hyperglycemia may adversely affect cancer outcomes and response to systemic thera...
Landscape of peripheral immune response induced by multimodal thermal therapy combined with chemoimmunotherapy in patients with early-stage HER2-negative breast cancer.
e12654 Background: Multimodal thermal therapy (MTT), consisting of alternated liquid nitrogen cooling and radiofrequency h...
Oncology drug shortages and disruptions to cancer treatment delivery in Mexico: A national oncologist survey.
1599 Background: Oncology drug shortages increasingly disrupt cancer care delivery worldwide, yet quantitative data descri...
Engineering tumor-infiltrating lymphocytes (TILs) via the T-Editor platform to enhance antitumor activity.
2643 Background: Tumor-infiltrating lymphocyte (TIL) therapy has demonstrated clinical potential in melanoma, cervical can...
A real-world study of <i>RET</i> fusion in patients with solid tumor.
e20678 Background: RET activates downstream oncogenic signaling pathways such as RAS/MAPK, which regulates essential cellu...